The National Institutes of Health today announced a $12 million award for outreach and engagement efforts in ethnic and racial minority communities disproportionately affected by the COVID-19 pandemic. The award to RTI International, a non-profit research institution, will support teams in 11 states established as part of the NIH Community Engagement Alliance (CEAL) Against COVID-19 Disparities. These teams have received initial funding to immediately create CEAL programs, and RTI will serve as the Technical and Administrative Support and Coordination (TASC) center.
The CEAL research teams will focus on COVID-19 awareness and education research, especially among African Americans, Hispanics/Latinos, and American Indians — populations that account for over half of all reported cases in the United States. They also will promote and facilitate the inclusion and participation of these groups in vaccine and therapeutic clinical trials to prevent and treat the disease.
The communities of special focus include counties in Alabama, Arizona, California, Florida, Georgia, Louisiana, Michigan, Mississippi, North Carolina, Tennessee and Texas.
“Addressing health disparities affecting racial and ethnic minority populations has long been a priority for NIH,” said NIH Director Francis S. Collins, M.D., Ph.D. “The burden of the COVID-19 pandemic borne by diverse communities, especially those that include Blacks and Latinos, makes clear the urgent need for treatments and vaccines that are effective for all Americans. Inclusive research that reflects the entire population is essential to this goal.”
CEAL is an NIH-wide effort led by the National Institute on Minority Health and Health Disparities (NIMHD) and the National Heart, Lung, and Blood Institute (NHLBI). It expands existing community outreach efforts already underway by NIH COVID-19 trial networks.
The CEAL research teams will leverage established relationships between NIH-funded researchers and local community-engaged leaders to help reach underserved communities that might not be located near COVID-19 clinical research recruitment sites.
“Building on the strength of local organizations, as well as our long-standing community-engaged research efforts, will help us communicate effectively to address disparities and support the proven resilience within communities,” said NIMHD Director Eliseo J. Pérez-Stable, M.D. “This work will help ensure people get accurate and trustworthy information about the virus, how to reduce its spread, and how to protect themselves and their families.”
CEAL research teams include NIH and other federally funded entities that have community engagement expertise, non-academic community-based organizations, Federally Qualified Health Centers (FQHCs(link is external)), state and/or local health departments, and others. Their goal is to quickly launch outreach efforts that can help reduce the impact of COVID-19 on the most vulnerable populations and to evaluate these efforts through community-engaged research.
“Since communities of color have been particularly affected, and also historically underrepresented in clinical research, it is essential that we encourage people to join COVID-19 research studies,” said NHLBI Director Gary Gibbons, M.D. “That’s why NIH is partnering with messengers who live, work, and worship in the same communities where the disease has caused the highest rates of sickness and death. In the middle of a pandemic, people need to hear familiar, trusted voices they know are advocating for their health and safety.”
For more information about CEAL, visit the NIH COVID-19 communities page.
The CEAL principal investigators and institutions are:
Mona N. Fouad, M.D., M.P.H.
University of Alabama at Birmingham
Sairam Parthasarathy, M.D.
University of Arizona College of Medicine, Tucson
Arleen F. Brown, M.D., Ph.D.
University of California, Los Angeles
Olveen Carrasquillo, M.D., M.P.H
University of Miami
Tabia Henry Akintobi, Ph.D., M.P.H.
Morehouse School of Medicine, Atlanta
Marie A. Krousel-Wood, M.D.
Tulane University, New Orleans
Erica Marsh, M.D.
University of Michigan, Ann Arbor
Caroline Compretta, Ph.D.
University of Mississippi Medical Center, Jackson
Anissa I. Vines, Ph.D.
University of North Carolina, Chapel Hill
Paul Juarez, Ph.D.
Meharry Medical College, Nashville, Tennessee
Jamboor Vishwanatha, Ph.D.
University of North Texas Health Science Center, Fort Worth
Linda Squiers, Ph.D.
Technical Lead, TASC
RTI International, Research Triangle Park, North Carolina
About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives. For more information, visit https://www.nhlbi.nih.gov.
About the National Institutes on Minority Health and Health Disparities (NIMHD): NIMHD leads scientific research to improve minority health and eliminate health disparities by conducting and supporting research; planning, reviewing, coordinating, and evaluating all minority health and health disparities research at NIH; promoting and supporting the training of a diverse research workforce; translating and disseminating research information; and fostering collaborations and partnerships. For more information about NIMHD, visit https://www.nimhd.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®